Foghorn Therapeutics Inc. FHTX · Stock Open Foghorn Therapeutics Inc. in new tab
Foghorn Therapeutics Inc. Analysis (FHTX)
Is Foghorn Therapeutics Inc. a good investment? Foghorn Therapeutics Inc. (FHTX) is currently trading at 4.61 USD. Market analysts have a consensus price target of 11.44 USD. This suggests a potential upside from current levels.
Earnings Schedule: Foghorn Therapeutics Inc. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is -1.10.
Investor FAQ
Does Foghorn Therapeutics Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Foghorn Therapeutics Inc.?
Foghorn Therapeutics Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of -1.17.
Company Profile
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Community Discussion